Genetic Variations of α-Methylacyl-CoA Racemase Are Associated with Sporadic Prostate Cancer Risk in Ethnically Homogenous Koreans
Table 6
AMACR (5p13) haplotypes and their association with prostate cancer risk.
Haplotype*
Cases (%)
Controls (%)
Crude OR (95% CI)
P value
Adjusted OR(95% CI)a
P value
12345-1[AGCAA]
147 (37.9)
116 (34.3)
Ref.
Ref.
12345-2[AGCGG]
116 (29.9)
103 (30.5)
0.89 (0.62–1.27)
0.5208
0.95 (0.60–1.50)
0.8205
12345-3[ATCGG]
56 (14.4)
47 (13.9)
0.94 (0.60–1.49)
0.7919
1.14 (0.62–2.10)
0.6743
12345-4[GGTGG]
33 (8.5)
39 (11.5)
0.67 (0.40–1.13)
0.1306
0.59 (0.31–1.13)
0.1108
12345-5[GGCGG]
11 (2.8)
20 (5.9)
0.43 (0.20–0.94)
0.0348
0.41 (0.17–1.00)
0.0489
12345-6[AGTGG]
18 (4.6)
9 (2.7)
1.58 (0.68–3.64)
0.2849
0.97 (0.35–2.74)
0.9603
12345-7[GGCAA]
7 (1.8)
3 (0.9)
1.84 (0.47–7.28)
0.3839
1.54 (0.28–8.36)
0.6190
Haplotype pair
12-2 [GG]
0 copies
145 (74.7)
110 (65.1)
Ref.
Ref.
1 or 2 copies
49 (25.3)
59 (34.9)
0.63 (0.40–0.99)
0.0455
0.51 (0.29–0.90)
0.0199
14-3 [GG]
0 copies
153 (78.9)
112 (66.3)
Ref.
Ref.
1 or 2 copies
41 (21.1)
57 (33.7)
0.53 (0.33 –0.84)
0.0074
0.43 (0.24–0.77)
0.0047
15-3 [GG]
0 copies
150 (77.3)
112 (66.3)
Ref.
Ref.
1 or 2 copies
44 (22.7)
57 (33.7)
0.58 (0.36–0.92)
0.0197
0.47 (0.27 –0.84)
0.0104
145-3 [GGG]
0 copies
150 (77.3)
112 (66.3)
Ref.
Ref.
1 or 2 copies
44 (22.7)
57 (33.7)
0.58 (0.36–0.92)
0.0197
0.47 (0.27 –0.84)
0.0104
1245-4 [GGGG]
0 copies
151 (77.8)
113 (66.9)
Ref.
Ref.
1 or 2 copies
43 (22.2)
56 (33.1)
0.57 (0.36–0.92)
0.0199
0.48 (0.27 –0.86)
0.0132
1345-4 [GCGG]
0 copies
182 (93.8)
148 (87.6)
Ref.
Ref.
1 or 2 copies
12 (6.2)
21 (12.4)
0.46 (0.22–0.98)
0.0428
0.40 (0.17–0.95)
0.0379
12345-5 [GGCGG]
0 copies
183 (94.3)
149 (88.2)
Ref.
Ref.
1 or 2 copies
11 (5.7)
20 (11.8)
0.45 (0.21–0.96)
0.0400
0.41 (0.17–0.99)
0.0472
Haplotypes with total frequencies of less than 1 percent were excluded in table. OR: odds ratio; CI: confidence interval; AMACR: (R)-alpha-methyl-CoA racemase. 1: rs2278008; 2: rs34677; 3: rs2287939; 4: rs10941112; 5: rs3195676. Adjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.
